FREE NEWSLETTER: Econintersect sends a nightly newsletter highlighting news events of the day, and providing a summary of new articles posted on the website. Econintersect will not sell or pass your email address to others per our privacy policy. You can cancel this subscription at any time by selecting the unsubscribing link in the footer of each email.

posted on 27 September 2016

Why Alzheimer's Research Is Failing To Hit Treatment Targets

from The Conversation

-- this post authored by Karen Marshall, University of Sussex

Since Alois Alzheimer first described a "peculiar severe disease" in 1901, research into dementia has grown at an astonishing rate. As the prevalence of Alzheimer's disease increases, the need for a treatment becomes more pressing and scientists trying to understand the disease are more accountable than ever.

While there has been significant investment and encouraging progress, therapies are still limited. And as the pressure on those affected by and working in the field of Alzheimer's intensifies, therapeutic goals seem increasingly elusive and sometimes contradictory.

In comparison to other diseases such as cancer, cardiovascular disease and HIV, finding treatments for Alzheimer's disease (AD) has been something of a biomedical flop. But measuring the achievements you get from research against the money and time expended is not straightforward. There is no way to predict a discovery timeline, and one clinical story may be longer than another. Nonetheless, costs need justification, and while pharmaceutical companies can pick and choose where they spend their money (and many are choosing not to invest in AD), academics need to defend their data to attract funding and continue the work they are convinced will reap benefits.

So can the failure of AD research to produce drugs be attributed to finance? Possibly. Dementia research is indisputably underfunded, relatively speaking. However, the important difference could be more molecular than monetary.

Cause and effect

Unlike cancer and HIV in particular, which are very well characterised experimentally, the cause (or causes) of AD, what the changes are that take place in the brain that lead to dysfunction, are still debated among scientists. Research has pointed the finger at potential culprits, but differentiating between those responsible and which get caught up as downstream effects is challenging. So while further and increased investment in research will inevitably reveal more on the causes, the lack of money may not be enough to explain why it remains so tough to decipher.

Being a disorder of the brain makes AD hard to study, diagnose and treat. Taking a biopsy from such an inaccessible organ is far more invasive than from a peripheral tumour. The pharmaceutical history of Alzheimer's disease is an interesting one. Although several symptomatic treatments are available, no disease-modifying drug has been approved which can slow, halt or reverse cognitive decline.

Research is continuously uncovering new targets and some of these are showing real promise in phase III trials. Genetic information along with a wealth of experimental data identified the amyloid beta protein as a possible molecular basis for AD. It is now the target of several therapeutic interventions. Nevertheless, none of these have fully passed through clinical trials.

All about targets and timing. john skewes/Flickr, CC BY-ND

There could be many reasons for the lack of success: is the target being reached? Is the target correct? Is there another target that needs to be reached at the same time? Is the target being reached, but too late?. But regardless of the science, these clinical studies generate disagreement and create commotion in an already tumultuous field. Assimilating the massive amounts of data published on the causes of Alzheimer's is impossible. Even the most open-minded researcher will have a theory they are obliged (and funded) to doggedly pursue, making it hard to challenge their personal status quo and which leaves the community as a whole with a set of conflicting ideas and irreconcilable data.


These conflicts do not remain in an academic silo. The rising incidence of Alzheimer's has come alongside a changing media which disseminates and discusses the results of research like never before. Increased media exposure is certainly positive in some respects; it gives the public information, helps to make scientists accountable, and stimulates important debate, but it can also be provocative.

Translating laboratory findings to the public domain can be tricky. Alexander Raths/Shutterstock

Much of the research that the public hears about is is contradictory and sometimes, although likely unintentionally, inflammatory. Headlines describing Alzheimer's as a transmissible disease are simultaneously fascinating and alarming. And of course, the cautious inferences and caveats often contained within research can be difficult to get across in the media.

Accessible knowledge helps shape opinions, but may not always provide a complete story, and can place a strain on the relationship between those inside and outside of the laboratory.

Of course, regardless of the immense challenge, dedicated and intense research into Alzheimer's disease must continue. High-risk, high-reward science is intellectually alluring and creates a competitive environment, a double-edged sword that can both promote and prevent scientific endeavour. There are certainly stepping stones forming in the swamp of information on Alzheimer's that will undoubtedly grow and coalesce; progress is inevitable despite the baffling complexity of the disease. Researchers will continue to agree, collaborate, argue and oppose but ultimately the goal is the same for all, to untangle the mysteries of this devastating disease.

The ConversationKaren Marshall, Research Fellow, University of Sussex

This article was originally published on The Conversation. Read the original article.

>>>>> Scroll down to view and make comments <<<<<<

Click here for Historical News Post Listing

Make a Comment

Econintersect wants your comments, data and opinion on the articles posted.  As the internet is a "war zone" of trolls, hackers and spammers - Econintersect must balance its defences against ease of commenting.  We have joined with Livefyre to manage our comment streams.

To comment, using Livefyre just click the "Sign In" button at the top-left corner of the comment box below. You can create a commenting account using your favorite social network such as Twitter, Facebook, Google+, LinkedIn or Open ID - or open a Livefyre account using your email address.

You can also comment using Facebook directly using he comment block below.

Econintersect Contributors


Print this page or create a PDF file of this page
Print Friendly and PDF

The growing use of ad blocking software is creating a shortfall in covering our fixed expenses. Please consider a donation to Econintersect to allow continuing output of quality and balanced financial and economic news and analysis.

Take a look at what is going on inside of
Main Home
Analysis Blog
Is Free Trade Harming the Economy?
Bank of England Endorses Post-Keynesian Endogenous Money Theory
News Blog
How To Easily ID Support And Resistance On Your Charts
Infographic Of The Day: Hollywood Vs. Real Life: How Realistic Are Romantic Comedies
Early Headlines: New Travel Ban, Trump And McCain On Media, Greek Tragedy, Iraq Moves On W. Mosul, US Pushes China On N. Korea, China Wants To Deal, Emoluments Test And More
New Seasonal Outlook Updates from NOAA and JAMSTEC Disagree ...
A Presser For The Ages
Level Of Migration To The United States Not Unprecedented
Earnings And Economic Reports: Week Starting 20 February 2017
Where People Use Voice Assistants
Organic Molecules Found On Giant Asteroid Ceres - Why That's Such A Huge Deal
The Shortest-Serving US National Security Advisors
What We Read Today 18 February 2017
America First, India Second
With Unconventional Weapons, Drones Hit Their Limits
Investing Blog
The Week Ahead: Trump And The Business Cycle
The Importance Of Quality In Diversification
Opinion Blog
Winter Olympics 2022: Beijing And China's Second 'Coming-Out Party'
Of Debt, Detriment, And Exorbitant Privilege
Precious Metals Blog
The Best Gold Stock To Buy Right Now
Live Markets
17Feb2017 Market Close: US Markets Close In The Green Surprising The Bearish Analysts, Monday Markets Will Be Closed For Presidents Day Holiday
Amazon Books & More

.... and keep up with economic news using our dynamic economic newspapers with the largest international coverage on the internet
Asia / Pacific
Middle East / Africa
USA Government



Analysis Blog
News Blog
Investing Blog
Opinion Blog
Precious Metals Blog
Markets Blog
Video of the Day


Asia / Pacific
Middle East / Africa
USA Government

RSS Feeds / Social Media

Combined Econintersect Feed

Free Newsletter

Marketplace - Books & More

Economic Forecast

Content Contribution



  Top Economics Site Contributor TalkMarkets Contributor Finance Blogs Free PageRank Checker Active Search Results Google+

This Web Page by Steven Hansen ---- Copyright 2010 - 2017 Econintersect LLC - all rights reserved